aspirin has been researched along with Cognitive Dysfunction in 23 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Cognitive Dysfunction: Diminished or impaired mental and/or intellectual function.
Excerpt | Relevance | Reference |
---|---|---|
"Aspirin does not have a large proportional effect on the risk of dementia." | 9.51 | Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. ( Armitage, J; Barton, J; Bowman, L; Buck, G; Collins, R; Haynes, R; Mafham, M; Offer, A; Parish, S; Stevens, W; Wallendszus, K, 2022) |
"To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals." | 9.34 | Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. ( Chong, TTJ; Ernst, ME; Kirpach, B; Lockery, JE; McNeil, JJ; Murray, AM; Nelson, MR; Newman, AB; Orchard, SG; Reid, CM; Ryan, J; Shah, RC; Storey, E; Trevaks, R; Ward, SA; Williamson, JD; Wolfe, R; Woods, RL, 2020) |
" In the overall trial rivaroxaban plus aspirin reduced ischemic stroke by 49% (0." | 7.96 | Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. ( A A Fox, K; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Casanova, A; Connolly, SJ; Dagenais, GR; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Hart, RG; Keltai, K; Keltai, M; Kim, JH; Liang, Y; Liu, L; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; O'Donnell, M; Piegas, LS; Pogosova, N; Probstfield, JL; Reeh, KW; Ryden, L; Sharma, M; Smith, EE; Störk, S; Tonkin, AM; Varigos, JD; Vinereanu, D; Yusuf, S; Zhu, J, 2020) |
"Aspirin does not have a large proportional effect on the risk of dementia." | 5.51 | Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. ( Armitage, J; Barton, J; Bowman, L; Buck, G; Collins, R; Haynes, R; Mafham, M; Offer, A; Parish, S; Stevens, W; Wallendszus, K, 2022) |
"Of the 1534 ischemic stroke patients who randomly assigned to aspirin or cilostazol treatment with best medical therapy by the PICASSO (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage) trial, 1240 with baseline mini-mental state examination (MMSE) scores were analysed retrospectively." | 5.34 | Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study. ( Hong, KS; Kang, DW; Kwon, HS; Kwon, SU; Lee, D; Lee, EJ; Lee, JS; Lee, MH; Lim, JS; Oh, MS; Yu, KH; Yu, S, 2020) |
"To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals." | 5.34 | Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. ( Chong, TTJ; Ernst, ME; Kirpach, B; Lockery, JE; McNeil, JJ; Murray, AM; Nelson, MR; Newman, AB; Orchard, SG; Reid, CM; Ryan, J; Shah, RC; Storey, E; Trevaks, R; Ward, SA; Williamson, JD; Wolfe, R; Woods, RL, 2020) |
" In the overall trial rivaroxaban plus aspirin reduced ischemic stroke by 49% (0." | 3.96 | Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. ( A A Fox, K; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Casanova, A; Connolly, SJ; Dagenais, GR; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Hart, RG; Keltai, K; Keltai, M; Kim, JH; Liang, Y; Liu, L; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; O'Donnell, M; Piegas, LS; Pogosova, N; Probstfield, JL; Reeh, KW; Ryden, L; Sharma, M; Smith, EE; Störk, S; Tonkin, AM; Varigos, JD; Vinereanu, D; Yusuf, S; Zhu, J, 2020) |
"The effects of B vitamins on mild cognitive impairment (MCI) patients' cognition have been mixed, suggesting the existence of moderating factors." | 3.11 | B Vitamin Supplementation Slows Cognitive Decline in Mild Cognitive Impairment Patients with Frontal Lobe Atrophy. ( Gong, X; Kwok, T; Luo, Y; Shi, L; Wu, Y, 2022) |
"Cerebral small vessel disease is a progressive disease of the brain's deep perforating blood vessels." | 2.82 | Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia. ( Chiang, LLW; Hafdi, M; Kwan, J; Myint, PK; Quinn, TJ; Wong, LS, 2022) |
"Aspirin co-treatment rescued DNMTs activation and BDNF IV hypermethylation, and mitigated the recession in BDNF mRNA and protein induced by B[a]P treatment." | 1.72 | Aspirin ameliorates the cognition impairment in mice following benzo[a]pyrene treatment via down-regulating BDNF IV methylation. ( Bai, J; Cao, J; Hao, Z; Li, H; Li, X; Li, Y; Liu, A; Wang, Z; Xia, N; Zhang, H; Zhang, Z, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (26.09) | 24.3611 |
2020's | 17 (73.91) | 2.80 |
Authors | Studies |
---|---|
Lin, X | 1 |
Banaszak-Holl, J | 1 |
Xie, J | 1 |
Ward, SA | 2 |
Brodaty, H | 1 |
Storey, E | 3 |
Shah, RC | 4 |
Murray, A | 2 |
Ryan, J | 5 |
Orchard, SG | 5 |
Fitzgerald, SM | 1 |
McNeil, JJ | 4 |
Mone, P | 1 |
Trimarco, B | 1 |
Santulli, G | 1 |
Wu, Y | 2 |
Smith, AD | 1 |
Refsum, H | 1 |
Kwok, T | 2 |
Broder, JC | 2 |
Lockery, JE | 2 |
Gilmartin-Thomas, JF | 1 |
Fravel, MA | 1 |
Owen, AJ | 1 |
Woods, RL | 4 |
Wolfe, R | 3 |
Murray, AM | 3 |
Ernst, ME | 4 |
Li, Y | 1 |
Cao, J | 1 |
Hao, Z | 1 |
Liu, A | 1 |
Li, X | 1 |
Li, H | 1 |
Xia, N | 1 |
Wang, Z | 1 |
Zhang, Z | 1 |
Bai, J | 1 |
Zhang, H | 1 |
Parish, S | 1 |
Mafham, M | 1 |
Offer, A | 1 |
Barton, J | 1 |
Wallendszus, K | 1 |
Stevens, W | 1 |
Buck, G | 1 |
Haynes, R | 1 |
Collins, R | 1 |
Bowman, L | 1 |
Armitage, J | 1 |
Kwan, J | 1 |
Hafdi, M | 1 |
Chiang, LLW | 1 |
Myint, PK | 1 |
Wong, LS | 1 |
Quinn, TJ | 1 |
Gong, X | 1 |
Shi, L | 1 |
Luo, Y | 1 |
Mehta, RS | 1 |
Kochar, B | 1 |
Zhou, Z | 2 |
Chung, P | 1 |
Yang, K | 1 |
Lockery, J | 1 |
Fravel, M | 1 |
Mahady, S | 1 |
Chan, AT | 1 |
Tonkin, AM | 2 |
Zoungas, S | 2 |
Lacaze, P | 2 |
Yu, C | 1 |
Watts, GF | 1 |
Hussain, SM | 1 |
Beilin, LJ | 1 |
Stocks, N | 1 |
Zhu, C | 1 |
Reid, CM | 2 |
Chong, TT | 1 |
Sood, A | 1 |
Sheets, KM | 1 |
Nelson, MR | 2 |
Kwon, HS | 1 |
Lee, D | 1 |
Lee, MH | 1 |
Yu, S | 1 |
Lim, JS | 1 |
Yu, KH | 1 |
Oh, MS | 1 |
Lee, JS | 1 |
Hong, KS | 1 |
Lee, EJ | 1 |
Kang, DW | 1 |
Kwon, SU | 1 |
Lee, TC | 1 |
Qian, M | 1 |
Liu, Y | 1 |
Graham, S | 1 |
Mann, DL | 1 |
Nakanishi, K | 1 |
Teerlink, JR | 1 |
Lip, GYH | 1 |
Freudenberger, RS | 1 |
Sacco, RL | 1 |
Mohr, JP | 1 |
Labovitz, AJ | 1 |
Ponikowski, P | 1 |
Lok, DJ | 1 |
Matsumoto, K | 1 |
Estol, C | 1 |
Anker, SD | 1 |
Pullicino, PM | 1 |
Buchsbaum, R | 1 |
Levin, B | 1 |
Thompson, JLP | 1 |
Homma, S | 1 |
Di Tullio, MR | 1 |
Knopman, DS | 1 |
Petersen, RC | 1 |
Chong, TTJ | 1 |
Williamson, JD | 1 |
Trevaks, R | 1 |
Kirpach, B | 1 |
Newman, AB | 1 |
Amidzic, A | 1 |
Tiro, N | 1 |
Sharma, M | 1 |
Hart, RG | 1 |
Smith, EE | 1 |
Bosch, J | 1 |
Eikelboom, JW | 1 |
Connolly, SJ | 1 |
Dyal, L | 1 |
Reeh, KW | 1 |
Casanova, A | 1 |
Diaz, R | 1 |
Lopez-Jaramillo, P | 1 |
Ertl, G | 1 |
Störk, S | 1 |
Dagenais, GR | 1 |
Lonn, EM | 1 |
Ryden, L | 1 |
Varigos, JD | 1 |
Bhatt, DL | 1 |
Branch, KRH | 1 |
Probstfield, JL | 1 |
Kim, JH | 1 |
O'Donnell, M | 1 |
Vinereanu, D | 1 |
A A Fox, K | 1 |
Liang, Y | 1 |
Liu, L | 1 |
Zhu, J | 1 |
Pogosova, N | 1 |
Maggioni, AP | 1 |
Avezum, A | 1 |
Piegas, LS | 1 |
Keltai, K | 1 |
Keltai, M | 1 |
Berkowitz, SD | 1 |
Yusuf, S | 1 |
Patel, S | 1 |
Sanborn, D | 1 |
Issa, M | 1 |
Weng, J | 1 |
Zhao, G | 1 |
Weng, L | 1 |
Guan, J | 1 |
Woods, R | 1 |
McNeil, J | 1 |
Ferrari, C | 1 |
Lombardi, G | 1 |
Polito, C | 1 |
Lucidi, G | 1 |
Bagnoli, S | 1 |
Piaceri, I | 1 |
Nacmias, B | 1 |
Berti, V | 1 |
Rizzuto, D | 1 |
Fratiglioni, L | 1 |
Sorbi, S | 1 |
Fink, HA | 1 |
Jutkowitz, E | 1 |
McCarten, JR | 1 |
Hemmy, LS | 1 |
Butler, M | 1 |
Davila, H | 1 |
Ratner, E | 1 |
Calvert, C | 1 |
Barclay, TR | 1 |
Brasure, M | 1 |
Nelson, VA | 1 |
Kane, RL | 1 |
Walker, AK | 1 |
Chang, A | 1 |
Ziegler, AI | 1 |
Dhillon, HM | 1 |
Vardy, JL | 1 |
Sloan, EK | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes[NCT00135226] | Phase 4 | 15,480 participants (Actual) | Interventional | 2005-03-31 | Active, not recruiting | ||
LACunar Intervention (LACI-2) Trial-2: Assessment of Safety and Efficacy of Cilostazol and Isosorbide Mononitrate to Prevent Recurrent Lacunar Stroke and Progression of Cerebral Small Vessel Disease.[NCT03451591] | Phase 2/Phase 3 | 363 participants (Actual) | Interventional | 2018-01-08 | Completed | ||
A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease[NCT01932203] | Phase 4 | 255 participants (Actual) | Interventional | 2013-07-17 | Active, not recruiting | ||
Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White[NCT00847860] | Phase 4 | 200 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
Stroke and Coated-Platelets - A Translational Research Initiative[NCT04698031] | Phase 4 | 152 participants (Anticipated) | Interventional | 2022-03-30 | Recruiting | ||
Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF Trial)[NCT03061006] | Phase 4 | 101 participants (Actual) | Interventional | 2017-04-03 | Completed | ||
Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial[NCT00041938] | Phase 3 | 2,305 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
Aspirin in Reducing Events in the Elderly[NCT01038583] | 19,114 participants (Actual) | Observational | 2010-01-31 | Active, not recruiting | |||
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
A Multidomain Intervention Program for Older People With Dementia: A Pilot Study[NCT04948450] | 60 participants (Anticipated) | Interventional | 2022-11-24 | Active, not recruiting | |||
Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.[NCT05262257] | Early Phase 1 | 120 participants (Anticipated) | Interventional | 2022-04-01 | Not yet recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Secondary efficacy assessments of aspirin involve intention-to-treat comparisons during the scheduled treatment period among all randomized participants on the first occurrence of:~Any incident gastrointestinal (GI) tract cancer (i.e. any GI cancer excluding pancreas and hepatobiliary), overall and after exclusion of the first three years of follow-up." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 157 |
Placebo Aspirin | 158 |
"Secondary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 versus placebo on the first occurrence of the expanded vascular endpoint of SVE or revascularization (including coronary and non-coronary revascularizations)." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 833 |
Placebo Aspirin | 936 |
Omega-3 | 882 |
Placebo Omega-3 | 887 |
"Incidence of fatal or non-fatal cancers. Any cancer excludes non-fatal non-melanoma skin cancer and non-fatal recurrence of a cancer that had occurred before randomization.~A single participant may have had multiple cancers." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 897 |
Placebo Aspirin | 887 |
Omega-3 | 894 |
Placebo Omega-3 | 890 |
Includes fatal and non-fatal events. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Omega-3 | 166 |
Placebo Omega-3 | 135 |
Includes fatal and non-fatal cancers. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 97 |
Placebo Aspirin | 96 |
Omega-3 | 103 |
Placebo Omega-3 | 90 |
Includes fatal and non-fatal renal, bladder, prostate, gynaecological and other GU cancers (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 332 |
Placebo Aspirin | 294 |
Omega-3 | 323 |
Placebo Omega-3 | 303 |
Includes fatal and non-fatal cancers. Includes leukaemia and lymphoma. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 88 |
Placebo Aspirin | 86 |
Omega-3 | 94 |
Placebo Omega-3 | 80 |
Includes fatal and non-fatal melanomas. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 50 |
Placebo Aspirin | 59 |
Omega-3 | 55 |
Placebo Omega-3 | 54 |
Includes fatal and non-fatal events, excludes atrial fibrillation. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Omega-3 | 83 |
Placebo Omega-3 | 99 |
Includes fatal and non-fatal cancers not included elsewhere (where the type of cancer is known). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 25 |
Placebo Aspirin | 30 |
Omega-3 | 23 |
Placebo Omega-3 | 32 |
Includes fatal and non-fatal cancers. Excludes cancers reported in the gastrointestinal tract category (see secondary outcome measure #4), and includes hepatobiliary and pancreatic cancers. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 87 |
Placebo Aspirin | 82 |
Includes fatal and non-fatal cancers. Includes lung and larynx cancer. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 101 |
Placebo Aspirin | 103 |
Omega-3 | 104 |
Placebo Omega-3 | 100 |
Includes fatal and non-fatal cancers of unknown type. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 26 |
Placebo Aspirin | 31 |
Omega-3 | 25 |
Placebo Omega-3 | 32 |
Fatal 'All stroke' events include deaths from: Haemorrhagic stroke (Intracerebral haemorrhage; Subarachnoid haemorrhage); Non-haemorrhagic stroke (Cerebral infarction; Stroke not specified as haemorrhage or infarction). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 38 |
Placebo Aspirin | 34 |
Omega-3 | 35 |
Placebo Omega-3 | 37 |
'All-cause mortality' includes all recorded deaths. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 748 |
Placebo Aspirin | 792 |
Omega-3 | 752 |
Placebo Omega-3 | 788 |
Fatal 'Cancer' events include any death attributed to cancer. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 309 |
Placebo Aspirin | 315 |
Omega-3 | 305 |
Placebo Omega-3 | 319 |
Fatal 'Coronary' events include deaths from: Acute MI and other CHD (unspecified Acute ischaemic heart disease; Atherosclerotic heart disease; Ischaemic cardiomyopathy; unspecified Chronic ischaemic heart disease). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 105 |
Placebo Aspirin | 122 |
Omega-3 | 100 |
Placebo Omega-3 | 127 |
Fatal 'External cause' events include deaths from: Injury; Fracture; Self harm; and Medical and surgical complications (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 18 |
Placebo Aspirin | 21 |
Omega-3 | 17 |
Placebo Omega-3 | 22 |
Fatal 'Other medical' events include deaths from: Non-vascular medical causes (excluding cancer and respiratory, including Fatal GI bleed or perforation); and deaths from Renal disease and Diabetes. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 126 |
Placebo Aspirin | 157 |
Omega-3 | 158 |
Placebo Omega-3 | 125 |
Fatal 'Other vascular' events include deaths from: Heart failure (excluding ischaemic cardiomyopathy); Other vascular death (excluding stroke; and Cardiac death (excluding CHD). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 67 |
Placebo Aspirin | 70 |
Omega-3 | 61 |
Placebo Omega-3 | 76 |
Fatal 'Respiratory' events include any death attributed to respiratory causes. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 82 |
Placebo Aspirin | 69 |
Omega-3 | 73 |
Placebo Omega-3 | 78 |
Any death for which the cause is not known. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 3 |
Placebo Aspirin | 4 |
Omega-3 | 3 |
Placebo Omega-3 | 4 |
"The primary safety assessments involve intention-to-treat comparisons among all randomized patients of allocation to aspirin versus placebo on the first occurrence of any major bleed, defined as:~any confirmed intracranial hemorrhage (including intracerebral, subarachnoid, subdural or any other intracranial hemorrhage); or~sight-threatening eye bleeding; or~any other serious bleeding episode." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 314 |
Placebo Aspirin | 245 |
"The primary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 fatty acids versus placebo on the first occurrence of any Serious Vascular Event (SVE), defined as:~non-fatal myocardial infarction; or~non-fatal stroke (excluding confirmed intracranial hemorrhage) or TIA; or~vascular death excluding confirmed intracranial hemorrhage (defined as International Classification of Diseases 10th revision [ICD-10] I00-52 or I63-99, i.e. excluding subarachnoid hemorrhage [I60], intracerebral hemorrhage [I61], and other non-traumatic intracranial hemorrhage [I62])." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 658 |
Placebo Aspirin | 743 |
Omega-3 | 689 |
Placebo Omega-3 | 712 |
The time, in years, from randomization to the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years. Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until the date of the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to 6 years
Intervention | events per 100 patient-years (Number) |
---|---|
Aspirin | 7.93 |
Warfarin | 7.47 |
Time, in years, from randomization to death component of secondary composite outcome. This measure counts only deaths that were not preceded by heart failure hospitalization, myocardial infarction, ischemic stroke, or intracerebral hemorrhage. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of death component of secondary composite outcome, up to 6 years
Intervention | events per 100 patient years (Number) |
---|---|
Aspirin | 4.41 |
Warfarin | 4.43 |
Time, in years, from date of randomization to date of heart failure hospitalization, up to 6 years. Includes hospitalizations for heart failure during follow-up that were not preceded by myocardial infarction. Event rate per 100 patient years = 100*(number of subjects with heart failure hospitalization)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of heart failure hospitalization component of secondary composite outcome, up to 6 years
Intervention | events per 100 patient years (Number) |
---|---|
Aspirin | 5.67 |
Warfarin | 6.79 |
Time, in years, from date of randomization to date of intracerebral hemorrhage component of secondary composite outcome. Includes only intracerebral hemorrhages not preceded by myocardial infarction or heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of intracerebral hemorrhage component of secondary composite outcome, up to 6 years
Intervention | events per 100 patient years (Number) |
---|---|
Aspirin | 0.06 |
Warfarin | 0.11 |
Ischemic stroke component of secondary composite endpoint. Includes only ischemic strokes that were not preceded by a myocardial infarction or heart failure hospitalization. The number of ischemic strokes that are components of the secondary outcome does not therefore match the number of ischemic strokes that are components of the primary outcome. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of ischemic stroke component of secondary composite outcome, up to 6 years
Intervention | events per 100 patient years (Number) |
---|---|
Aspirin | 1.14 |
Warfarin | 0.57 |
Time, in years, from date of randomization to date of myocardial infarction, up to 6 years. Includes only myocardial infarctions that occurred during follow-up, before any heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with myocardial infarction)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of myocardial infarction component of secondary composite outcome, up to 6 years
Intervention | events per 100 patient years (Number) |
---|---|
Aspirin | 0.87 |
Warfarin | 0.80 |
"The time, in years, from date of randomization to the date of the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to 6 years.~Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25." (NCT00041938)
Timeframe: From randomization to the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years.
Intervention | events per 100 patient-years (Number) |
---|---|
Aspirin | 12.15 |
Warfarin | 12.70 |
Time, in years, from date of randomization to date of death component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of death component of primary composite outcome, up to 6 years
Intervention | events per 100 patient-years (Number) |
---|---|
Aspirin | 6.52 |
Warfarin | 6.63 |
Time, in years, from date of randomization to date of intracerebral hemorrhage component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of intracerebral hemorrhage component of primary composite outcome, up to 6 years
Intervention | rate per 100 patient years (Number) |
---|---|
Aspirin | 0.05 |
Warfarin | 0.12 |
Time, in years, from date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years
Intervention | rate per 100 patient years (Number) |
---|---|
Aspirin | 1.36 |
Warfarin | 0.72 |
Rate/100 patient-years of major hemorrhage. Includes all major hemorrhages in any patient. Major hemorrhage was defined as intracerebral, epidural, subdural, subarachnoid, spinal intramedullary, or retinal hemorrhage; any other bleeding causing a decline in the hemoglobin level of more than 2 g per deciliter in 48 hours; or bleeding requiring transfusion of 2 or more units of whole blood, hospitalization, or surgical intervention. Event rate per 100 patient years = 100*(number of major hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until end of scheduled follow-up, up to 6 years
Intervention | events per 100 patient years (Number) |
---|---|
Aspirin | 0.87 |
Warfarin | 1.78 |
Rate per 100 patient years of minor hemorrhage. Includes all minor hemorrhages. Minor hemorrhage was defined as any non-major hemorrhage. Event rate per 100 patient years = 100*(number of minor hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until the end of scheduled follow-up, up to 6 years
Intervention | events per 100 patient-years (Number) |
---|---|
Aspirin | 7.34 |
Warfarin | 11.6 |
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
Intervention | Participants (Count of Participants) |
---|---|
Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
Rivaroxaban 5mg + Aspirin Placebo | 366 |
Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
Intervention | Participants (Count of Participants) |
---|---|
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
Intervention | Participants (Count of Participants) |
---|---|
Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
Rivaroxaban 5mg + Aspirin Placebo | 453 |
Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
Intervention | Participants (Count of Participants) |
---|---|
Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
Rivaroxaban 5mg + Aspirin Placebo | 397 |
Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
Intervention | Participants (Count of Participants) |
---|---|
Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
Rivaroxaban 5mg + Aspirin Placebo | 448 |
Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
Intervention | Participants (Count of Participants) |
---|---|
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
Intervention | Participants (Count of Participants) |
---|---|
Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
Rivaroxaban 5mg + Aspirin Placebo | 255 |
Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
Intervention | Participants (Count of Participants) |
---|---|
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
2 reviews available for aspirin and Cognitive Dysfunction
Article | Year |
---|---|
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.
Topics: Aspirin; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia; Humans; Neuroimaging; Plat | 2022 |
Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cholin | 2018 |
Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cholin | 2018 |
Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cholin | 2018 |
Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cholin | 2018 |
7 trials available for aspirin and Cognitive Dysfunction
Article | Year |
---|---|
Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial.
Topics: Aspirin; Cognition; Cognitive Dysfunction; Dementia; Diabetes Mellitus; Humans | 2022 |
B Vitamin Supplementation Slows Cognitive Decline in Mild Cognitive Impairment Patients with Frontal Lobe Atrophy.
Topics: Aspirin; Atrophy; Cognition; Cognitive Dysfunction; Dietary Supplements; Folic Acid; Frontal Lobe; H | 2022 |
Association of Proton Pump Inhibitor Use With Incident Dementia and Cognitive Decline in Older Adults: A Prospective Cohort Study.
Topics: Aged; Aspirin; Cognition; Cognitive Dysfunction; Humans; Prospective Studies; Proton Pump Inhibitors | 2023 |
Association Between Triglycerides and Risk of Dementia in Community-Dwelling Older Adults: A Prospective Cohort Study.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Aspirin; Cognition; Cognitive Dysfunction; Female; Human | 2023 |
Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study.
Topics: Aged; Aspirin; Cilostazol; Cognitive Dysfunction; Female; Fibrinolytic Agents; Humans; Male; Middle | 2020 |
Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cognitive Dysfunction; De | 2020 |
Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial.
Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Cardi | 2013 |
14 other studies available for aspirin and Cognitive Dysfunction
Article | Year |
---|---|
Similar mortality risk in incident cognitive impairment and dementia: Evidence from the ASPirin in Reducing Events in the Elderly (ASPREE) trial.
Topics: Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Cognitive Dysfunction; Dementi | 2021 |
Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Cognitive Dysfunction; Dementia; Humans; Warfar | 2022 |
Effectiveness of B Vitamins and Their Interactions with Aspirin in Improving Cognitive Functioning in Older People with Mild Cognitive Impairment: Pooled Post-Hoc Analyses of Two Randomized Trials.
Topics: Aged; Aspirin; Cognition; Cognitive Dysfunction; Humans; Randomized Controlled Trials as Topic; Vita | 2021 |
Anticholinergic medication burden and cognitive function in participants of the ASPREE study.
Topics: Aged; Aged, 80 and over; Aspirin; Cholinergic Antagonists; Cognition; Cognitive Dysfunction; Disable | 2022 |
Aspirin ameliorates the cognition impairment in mice following benzo[a]pyrene treatment via down-regulating BDNF IV methylation.
Topics: Animals; Aspirin; Benzo(a)pyrene; Brain-Derived Neurotrophic Factor; Cognition; Cognitive Dysfunctio | 2022 |
Cognitive Decline Over Time in Patients With Systolic Heart Failure: Insights From WARCEF.
Topics: Aged; Anticoagulants; Aspirin; Cognitive Dysfunction; Female; Fibrinolytic Agents; Heart Failure, Sy | 2019 |
The quest for dementia prevention does not include an aspirin a day.
Topics: Aspirin; Cognitive Dysfunction; Dementia, Vascular; Humans | 2020 |
Kinking of Bilateral Internal Carotid Arteries as Cause of Cognitive Dysfunction.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Bosnia and Herzegovina; Bromazepam; Carotid Artery, | 2020 |
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Topics: Aged; Aspirin; Brain; Brain Infarction; Cognitive Dysfunction; Drug Therapy, Combination; Factor Xa | 2020 |
57-Year-Old Woman With Weakness and Word-Finding Difficulties.
Topics: Adenocarcinoma, Clear Cell; Antibodies, Antiphospholipid; Aspirin; Biomarkers, Tumor; Cerebral Infar | 2021 |
Aspirin using was associated with slower cognitive decline in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cog | 2021 |
The genomic potential of the Aspirin in Reducing Events in the Elderly and Statins in Reducing Events in the Elderly studies.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Biological Specimen Banks; Cardio | 2017 |
Alzheimer's Disease Progression: Factors Influencing Cognitive Decline.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoprotein E4; Aspirin; Cognitive Dysfuncti | 2018 |
Low dose aspirin blocks breast cancer-induced cognitive impairment in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Behavior, Animal; Cognitive Dysfunction; | 2018 |